IL-6 as a keystone cytokine in health and disease - PubMed (original) (raw)
Review
doi: 10.1038/ni.3153.
Affiliations
- PMID: 25898198
- DOI: 10.1038/ni.3153
Review
IL-6 as a keystone cytokine in health and disease
Christopher A Hunter et al. Nat Immunol. 2015 May.
Erratum in
- Corrigendum: IL-6 as a keystone cytokine in health and disease.
Hunter CA, Jones SA. Hunter CA, et al. Nat Immunol. 2017 Oct 18;18(11):1271. doi: 10.1038/ni1117-1271b. Nat Immunol. 2017. PMID: 29044237
Abstract
Interleukin 6 (IL-6) has a broad effect on cells of the immune system and those not of the immune system and often displays hormone-like characteristics that affect homeostatic processes. IL-6 has context-dependent pro- and anti-inflammatory properties and is now regarded as a prominent target for clinical intervention. However, the signaling cassette that controls the activity of IL-6 is complicated, and distinct intervention strategies can inhibit this pathway. Clinical experience with antagonists of IL-6 has raised new questions about how and when to block this cytokine to improve disease outcome and patient wellbeing. Here we discuss the effect of IL-6 on innate and adaptive immunity and the possible advantages of various antagonists of IL-6 and consider how the immunobiology of IL-6 may inform clinical decisions.
Similar articles
- Interleukin-19 is a negative regulator of innate immunity and critical for colonic protection.
Azuma YT, Matsuo Y, Nakajima H, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Takeuchi T. Azuma YT, et al. J Pharmacol Sci. 2011;115(2):105-11. doi: 10.1254/jphs.10r02cr. Epub 2010 Dec 9. J Pharmacol Sci. 2011. PMID: 21157117 Review. - Specific targeting of IL-6 signalling pathway: a new way to treat IBD?
Desreumaux P. Desreumaux P. Gut. 2000 Oct;47(4):465-6. doi: 10.1136/gut.47.4.465. Gut. 2000. PMID: 10986204 Free PMC article. No abstract available. - Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target.
Allocca M, Jovani M, Fiorino G, Schreiber S, Danese S. Allocca M, et al. Curr Drug Targets. 2013 Nov;14(12):1508-21. doi: 10.2174/13894501113146660224. Curr Drug Targets. 2013. PMID: 24102406 Review. - Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Rose-John S, Mitsuyama K, Matsumoto S, Thaiss WM, Scheller J. Rose-John S, et al. Curr Pharm Des. 2009;15(18):2095-103. doi: 10.2174/138161209788489140. Curr Pharm Des. 2009. PMID: 19519447 Review. - Innate immune signals in autoimmune and autoinflammatory uveitis.
Rosenbaum JT, Kim HW. Rosenbaum JT, et al. Int Rev Immunol. 2013 Feb;32(1):68-75. doi: 10.3109/08830185.2012.750132. Int Rev Immunol. 2013. PMID: 23360159 Review.
Cited by
- Yinjia pills inhibits the malignant biological behavior of HeLa cells through PKM2-medicated inhibition of JAK/STAT3 pathway.
Shi Y, Min X, Li Y, Guo L, Cai Z, Li D, Jiang X, Feng N, Li X, Yang X. Shi Y, et al. Cytotechnology. 2025 Feb;77(1):5. doi: 10.1007/s10616-024-00668-5. Epub 2024 Nov 20. Cytotechnology. 2025. PMID: 39575323 Free PMC article. - CD38 modulates cytokine secretion by NK cells through the Sirt1/NF-κB pathway, suppressing immune surveillance in colorectal cancer.
Wang X, Song X, Fang K, Chang X. Wang X, et al. Sci Rep. 2024 Nov 20;14(1):28702. doi: 10.1038/s41598-024-79008-8. Sci Rep. 2024. PMID: 39562615 Free PMC article. - Novel perspectives on the link between obesity and cancer risk: from mechanisms to clinical implications.
Shi X, Jiang A, Qiu Z, Lin A, Liu Z, Zhu L, Mou W, Cheng Q, Zhang J, Miao K, Luo P. Shi X, et al. Front Med. 2024 Dec;18(6):945-968. doi: 10.1007/s11684-024-1094-2. Epub 2024 Nov 14. Front Med. 2024. PMID: 39542988 Review. - C-reactive protein kinetics as a predictive marker for long-term outcome of immune checkpoint inhibitors in oesophagogastric cancer.
Nose Y, Saito T, Kurokawa Y, Takahashi T, Yamamoto K, Momose K, Yamashita K, Tanaka K, Makino T, Eguchi H, Doki Y, Wada H. Nose Y, et al. BJC Rep. 2023 Aug 2;1(1):7. doi: 10.1038/s44276-023-00005-x. BJC Rep. 2023. PMID: 39516365 Free PMC article. - Vagus nerve stimulation: Novel concept for the treatment of glioblastoma and solid cancers by cytokine (interleukin-6) reduction, attenuating the SASP, enhancing tumor immunity.
Brem S. Brem S. Brain Behav Immun Health. 2024 Sep 17;42:100859. doi: 10.1016/j.bbih.2024.100859. eCollection 2024 Dec. Brain Behav Immun Health. 2024. PMID: 39512605 Free PMC article. Review.
References
- Eur J Immunol. 2013 Oct;43(10):2613-25 - PubMed
- Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9409-14 - PubMed
- J Immunol. 2009 Aug 1;183(3):1732-8 - PubMed
- Am J Pathol. 1997 Sep;151(3):689-96 - PubMed
- J Biol Chem. 2013 May 24;288(21):14756-68 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 19796/ARC_/Arthritis Research UK/United Kingdom
- 19796/VAC_/Versus Arthritis/United Kingdom
- 20770/ARC_/Arthritis Research UK/United Kingdom
- 20770/VAC_/Versus Arthritis/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials